|
시장보고서
상품코드
2078329
담도 종양 시장 규모, 점유율 및 성장 분석 : 종양 유형별, 치료법별, 병기별, 최종사용자별, 유통경로별, 지역별 - 업계 예측(2026-2033년)Biliary Tumor Market Size, Share, and Growth Analysis, By Tumor Type (Cholangiocarcinoma, Gallbladder Cancer), By Treatment (Chemotherapy, Targeted Therapy ), By Stage, By End-User, By Distribution, By Region - Industry Forecast 2026-2033 |
||||||
세계의 담도 종양 시장 규모는 2024년에 18억 2,000만 달러로 평가되었고, 2025년 20억 1,000만 달러에서 2033년까지 45억 2,000만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 10.62%를 기록할 전망입니다.
세계 담도 종양 시장은 담관이나 담낭에 발생하는 악성 종양의 치료를 목적으로 하는 다양한 진단법, 수술 기구 및 표적 치료법을 포괄하고 있습니다. 고령화와 현대인의 생활 방식과 관련하여 사망률이 높고 발병률도 증가하고 있어, 이 시장의 중요성은 점점 더 커지고 있습니다. 진단 지연으로 인해 발생했던 초기 과제는 내시경 초음파 검사나 차세대 염기서열 분석 등의 기술 발전으로 완화되었으며, 초점은 정밀 의학으로 옮겨가고 있습니다. 주요 성장 요인으로는 FGFR2 융합이나 IDH1 변이 등의 유전자 변이에 대응하는 표적 치료제의 탄탄한 파이프라인을 들 수 있으며, 이를 통해 환자의 예후가 개선되고 있습니다. 이러한 발전에 힘입어 암 치료 센터에서의 도입이 확대되고, 멀티플렉스 분석법에 대한 수요가 촉진되며, 진단 기술에 대한 투자가 활성화됨에 따라 신흥국 및 전 세계 각국의 경제권에서 시장 전체의 확대가 뒷받침되고 있습니다.
세계 담도 종양 시장의 성장 요인
다양한 지역에서 담도 종양의 발생이 증가하고 있다는 사실은 확고한 치료 전략이 시급히 필요함을 여실히 보여주고 있으며, 의료 종사자들의 치료 선택지 확대와 다학제적 협력을 통한 관리 모델의 도입을 촉진하고 있습니다. 환자와 임상의들의 인식 제고는 조기 진단을 촉진하고, 기존 치료법과 혁신적인 치료법 모두에 대한 적극적인 접근을 뒷받침하고 있습니다. 이러한 추세는 개발 기간을 단축할 뿐만 아니라, 시장에 진출하는 기업들의 유통망을 강화하여 전 세계적인 성장을 더욱 촉진하고 있습니다. 또한, 산학 간 협력 체제뿐만 아니라 지식 공유 촉진 및 규제 당국의 승인 절차 신속화도 담도 종양 시장 전체의 성장세에 크게 기여하고 있습니다.
세계 담도 종양 시장의 제약 요인
세계 담도 종양 시장은 표적 치료에 따른 고비용으로 인해 환자와 의료 시스템 양측 모두에 재정적 장벽이 발생하고 있어 큰 과제에 직면해 있습니다. 이러한 고액의 비용은 종종 이러한 첨단 치료법의 도입을 저해하여, 의료 제공업체들이 혁신적인 선택지 대신 기존의 치료법을 선택하도록 만들고 있습니다. 이러한 추세는 제조업체의 수익 창출 가능성을 제한하고, 신제품 연구 개발에 대한 투자 능력에 부정적인 영향을 미치고 있습니다. 게다가 이러한 재정적 부담은 의료 정책 결정에도 영향을 미쳐, 고가의 치료법을 표준 진료에 도입하는 데 있어 보다 신중한 태도가 요구되게 되며, 결국 시장의 전반적인 성장 전망을 제약하게 됩니다.
세계 담도 종양 시장 동향
세계 담도 종양 시장에서는 환자의 분자적 특성 평가 정확도를 높이기 위한 통합 유전체 프로파일링으로의 뚜렷한 추세가 나타나고 있습니다. 이러한 진화를 통해 의료 서비스 제공업체는 치료 성과를 높이는 동시에 부작용을 줄일 수 있는 맞춤형 치료 전략을 수립할 수 있게 됩니다. 그 결과, 제약사들은 표적 치료제 파이프라인 확충에 더욱 주력하는 한편, 진단 기업들은 신뢰성이 높은 동반 진단 검사 개발에 투자하고 있으며, 이를 통해 각 지역에서 의약품 도입을 가속화하는 협업 생태계가 조성되고 있습니다. 이러한 시너지 효과는 임상의의 의사결정 효율성을 높일 뿐만 아니라, 담도 종양 관리에 있어 비용 대비 효과가 높고 치료 성과를 중시하는 지불 모델을 도입하려는 보험사의 목표와도 부합합니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 담도 종양 시장 규모 : 종양 유형별
세계의 담도 종양 시장 규모 : 치료별
세계의 담도 종양 시장 규모 : 스테이지별
세계의 담도 종양 시장 규모 : 최종사용자별
세계의 담도 종양 시장 규모 : 유통별
세계의 담도 종양 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.07.08Global Biliary Tumor Market size was valued at USD 1.82 Billion in 2024 and is poised to grow from USD 2.01 Billion in 2025 to USD 4.52 Billion by 2033, growing at a CAGR of 10.62% during the forecast period (2026-2033).
The global biliary tumor market encompasses a range of diagnostics, surgical tools, and targeted therapies aimed at treating malignancies affecting the bile ducts and gallbladder. This market is increasingly pivotal due to high mortality rates and rising incidences linked to aging populations and modern lifestyles. The initial challenges posed by late detection have been mitigated by advancements like endoscopic ultrasound and next-generation sequencing, shifting the focus toward precision medicine. Key growth drivers include a robust pipeline of targeted therapies that address genetic mutations such as FGFR2 fusions and IDH1 mutations, leading to improved patient outcomes. This evolution fosters increased adoption among oncology centers, stimulates demand for multiplex assays, and encourages investment in diagnostics, which fuels overall market expansion in emerging and global economies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biliary Tumor market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biliary Tumor Market Segments Analysis
Global biliary tumor market is segmented by tumor type, treatment, stage, end-user, distribution and region. Based on tumor type, the market is segmented into Cholangiocarcinoma (CCA), Gallbladder Cancer and Ampullary Cancer. Based on treatment, the market is segmented into Chemotherapy (Gemcitabine+Cisplatin), Targeted Therapy (FGFR2, IDH1) and Immunotherapy. Based on stage, the market is segmented into Localized, Locally Advanced and Metastatic. Based on end-user, the market is segmented into Oncology Centers and Hospitals. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Biliary Tumor Market
The increasing occurrence of biliary tumors across various regions underscores the urgent need for robust therapeutic strategies, prompting an expansion of treatment options and the adoption of multidisciplinary management models by healthcare professionals. Heightened awareness among patients and clinicians facilitates earlier diagnosis and fosters a proactive approach toward both established and innovative interventions. This trend not only accelerates development timelines but also enhances distribution networks for market participants, further driving global growth. Additionally, a collaborative environment between academia and industry, along with improved knowledge sharing and expedited regulatory approvals, significantly contributes to the overall momentum of the biliary tumor market.
Restraints in the Global Biliary Tumor Market
The global biliary tumor market faces significant challenges due to the elevated costs associated with targeted therapies, which create financial obstacles for both patients and healthcare systems. Such high expenses often hinder the adoption of these advanced treatments, pushing providers towards conventional therapies instead of innovative options. This trend limits manufacturers' revenue potential, adversely affecting their capacity to invest in research and development for new products. Furthermore, the financial strain influences health policy decisions, prompting a more cautious stance towards integrating expensive therapies into standard care practices, ultimately constraining the overall growth prospects of the market.
Market Trends of the Global Biliary Tumor Market
The global biliary tumor market is witnessing a significant trend towards integrated genomic profiling, which enhances the precision of molecular characterization in patients. This evolution enables healthcare providers to develop personalized treatment strategies that improve outcomes while reducing adverse effects. Consequently, pharmaceutical companies are increasingly focused on expanding their pipeline of targeted therapies, while diagnostic firms invest in developing robust companion tests, fostering a collaborative ecosystem that accelerates drug adoption across various regions. This synergy not only facilitates more streamlined decision-making for clinicians but also aligns with payers' objectives to implement cost-effective, outcome-driven payment models in the management of biliary tumors.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Biliary Tumor Market Size by Tumor Type & CAGR (2026-2033)
- Market Overview
- Cholangiocarcinoma (CCA)
- Gallbladder Cancer
- Ampullary Cancer
Global Biliary Tumor Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Chemotherapy (Gemcitabine+Cisplatin)
- Targeted Therapy (FGFR2, IDH1)
- Immunotherapy
Global Biliary Tumor Market Size by Stage & CAGR (2026-2033)
- Market Overview
- Localized
- Locally Advanced
- Metastatic
Global Biliary Tumor Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Oncology Centers
- Hospitals
Global Biliary Tumor Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
Global Biliary Tumor Market Size & CAGR (2026-2033)
- North America (Tumor Type, Treatment, Stage, End-User, Distribution)
- US
- Canada
- Europe (Tumor Type, Treatment, Stage, End-User, Distribution)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Tumor Type, Treatment, Stage, End-User, Distribution)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Tumor Type, Treatment, Stage, End-User, Distribution)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Tumor Type, Treatment, Stage, End-User, Distribution)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Incyte Corporation (Pemigatinib)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca (Imfinzi)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agios Pharmaceuticals (Ivosidenib)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QED Therapeutics (Infigratinib)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Deciphera Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Relay Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Basilea Pharmaceutica
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zymeworks
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TransEnterix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Turning Point Therapeutics (BMS)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Elevation Oncology
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Inhibrx Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pieris Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Prelude Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- G1 Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
